Alzamend Neuro (ALZN) Stock Overview
A clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
ALZN Community Fair Values
Create NarrativeSee what 9 others think this stock is worth. Follow their fair value or set your own to get alerts.
Alzamend Neuro, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$2.54 |
| 52 Week High | US$15.21 |
| 52 Week Low | US$2.06 |
| Beta | -0.28 |
| 1 Month Change | 0.40% |
| 3 Month Change | 6.72% |
| 1 Year Change | -82.90% |
| 3 Year Change | -99.82% |
| 5 Year Change | n/a |
| Change since IPO | -99.99% |
Recent News & Updates
Recent updates
Alzamend Neuro's Novel Lithium Formulation Will Target Major Mental Health Challenges
Catalysts AL001 : a novel lithium formulation targeting Alzheimer's disease, Bipolar Disorder, Major Depressive Disorder (MDD), and PTSD. Phase II studies show promising safety/efficacy, with trials ongoing as of 2025.Is Alzamend Neuro (NASDAQ:ALZN) In A Good Position To Deliver On Growth Plans?
Jul 26
Is Alzamend Neuro (NASDAQ:ALZN) In A Good Position To Deliver On Growth Plans?
Mar 20We're Not Very Worried About Alzamend Neuro's (NASDAQ:ALZN) Cash Burn Rate
Oct 14Alzamend stock falls amid start of AL001 dosing in healthy people in Alzheimer's trial
Oct 05Alzamend seeks FDA nod for early-stage trial of its therapy for Alzheimer’s type dementia
Sep 29Alzamend Neuro receives positive pre-IND response from FDA for AL001
Jul 18Alzamend: Biotech To Watch With 2 Drugs Targeting Multi-Billion Dollar Alzheimer's Market
Dec 18Shareholder Returns
| ALZN | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 3.7% | 0.8% | -0.9% |
| 1Y | -82.9% | 2.6% | 20.1% |
Return vs Industry: ALZN underperformed the US Biotechs industry which returned 4% over the past year.
Return vs Market: ALZN underperformed the US Market which returned 20.3% over the past year.
Price Volatility
| ALZN volatility | |
|---|---|
| ALZN Average Weekly Movement | 7.7% |
| Biotechs Industry Average Movement | 10.7% |
| Market Average Movement | 6.5% |
| 10% most volatile stocks in US Market | 17.4% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: ALZN has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: ALZN's weekly volatility has decreased from 15% to 8% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2016 | 6 | Stephan Jackman | www.alzamend.com |
Alzamend Neuro, Inc., a clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. Its pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer’s, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient’s immunological system to combat Alzheimer’s disease. Alzamend Neuro, Inc. was incorporated in 2016 and is headquartered in Atlanta, Georgia.
Alzamend Neuro, Inc. Fundamentals Summary
| ALZN fundamental statistics | |
|---|---|
| Market cap | US$9.62m |
| Earnings (TTM) | -US$6.83m |
| Revenue (TTM) | n/a |
Is ALZN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ALZN income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$6.83m |
| Earnings | -US$6.83m |
Last Reported Earnings
Jul 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.80 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did ALZN perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/11/03 23:14 |
| End of Day Share Price | 2025/11/03 00:00 |
| Earnings | 2025/07/31 |
| Annual Earnings | 2025/04/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Alzamend Neuro, Inc. is covered by 2 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Edward Woo | Ascendiant Capital Markets LLC |
| Michael Okunewitch | Maxim Group |